scholarly journals Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

Leukemia ◽  
2017 ◽  
Vol 31 (12) ◽  
pp. 2791-2798 ◽  
Author(s):  
A Dispenzieri ◽  
C Tong ◽  
B LaPlant ◽  
M Q Lacy ◽  
K Laumann ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Measles Virus ◽  
Phase I Trial ◽  
Sodium Iodide ◽  
Genetically Engineered ◽  
Systemic Administration ◽  
Sodium Iodide Symporter ◽  
Refractory Multiple Myeloma

GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial

2001 ◽  
Vol 127 (10) ◽  
pp. 619-624 ◽  
Author(s):  
Kate Sandstrom ◽  
Paul Elson ◽  
Denise McLain ◽  
Lisa Rybicki ◽  
Ronald Bukowski ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Trial ◽  
Refractory Multiple Myeloma ◽  
Gm Csf

Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 8076-8076 ◽  
Author(s):  
S. Lonial ◽  
R. Vij ◽  
T. Facon ◽  
P. Moreau ◽  
X. Leleu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Trial ◽  
Low Dose ◽  
Refractory Multiple Myeloma

Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 8013-8013 ◽  
Author(s):  
Rachid C. Baz ◽  
Kenneth H. Shain ◽  
Melissa Alsina ◽  
Jason Brayer ◽  
Tami Rashal ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Trial ◽  
Liposomal Doxorubicin ◽  
Refractory Multiple Myeloma

scholarly journals A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

2015 ◽  
Vol 21 (18) ◽  
pp. 4055-4061 ◽  
Author(s):  
Don M. Benson ◽  
Adam D. Cohen ◽  
Sundar Jagannath ◽  
Nikhil C. Munshi ◽  
Gary Spitzer ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Trial ◽  
Refractory Multiple Myeloma

scholarly journals Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects

2018 ◽  
Vol 18 (2) ◽  
pp. 177-187 ◽  
Author(s):  
Pavlos Msaouel ◽  
Mateusz Opyrchal ◽  
Angela Dispenzieri ◽  
Kah Whye Peng ◽  
Mark J. Federspiel ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Measles Virus ◽  
Sodium Iodide ◽  
Clinical Results ◽  
Genetically Engineered ◽  
Current Status ◽  
Sodium Iodide Symporter ◽  
Nerve Sheath Tumors ◽  
Peripheral Nerve Sheath Tumors ◽  
Cancer Breast

Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1179-1179 ◽  
Author(s):  
Paul G. Richardson ◽  
Constantine S. Mitsiades ◽  
Kathleen Colson ◽  
Eileen Reilly ◽  
Laura McBride ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Stable Disease ◽  
Phase I Trial ◽  
The United States ◽  
Maximum Tolerated Dose ◽  
Marrow Transplant ◽  
Cutaneous Manifestations ◽  
Refractory Multiple Myeloma ◽  
Systemic Therapies

Abstract Background: The histone deacetylase inhibitor vorinostat was approved by the United States FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following 2 systemic therapies. Vorinostat has also demonstrated promising preclinical activity in multiple myeloma. Patients and Methods: A Phase I trial of oral vorinostat 200, 250 or 300 mg bid for 5 days each week of a 4 week cycle or 200, 300, or 400 mg bid for 14 days/3 week cycle until progressive disease or intolerable toxicity was conducted. Patients with measurable, relapsed and/or refractory multiple myeloma with adequate hematologic, hepatic, and renal function were eligible. The objectives were to determine the maximum tolerated dose (MTD) on each of the schedules and assess activity and safety. Results: Thirteen patients (median age, 63 years; median 7 prior systemic therapies) were enrolled. The MTDs were not determined due to early termination of the study due to the decision of the sponsor. One patient (250 mg bid 5 days/week) developed dose-limiting toxicity (DLT) of grade 3 fatigue. There were no other DLTs and the maximum administered doses were 250 mg bid for 5 days each week of a 4-week cycle and 200 mg bid for 14 days/3-week cycle. Common drug-related adverse experiences included fatigue (69%), anorexia (62%), dehydration (46%), diarrhea (46%), and nausea (38%) and were mostly grade ≤ 2. Of 10 evaluable patients, 1 had a minimal response and 9 had stable disease (Table 1). Conclusions: Oral vorinostat was generally well tolerated at 250 mg bid for 5 days each week of a 4 week cycle or 200 mg bid for 14 days/3 week cycle in patients with advanced multiple myeloma. Modest activity was demonstrated in relapsed and/or refractory multiple myeloma and combination studies with other anti-myeloma agents are warranted. Table 1. Clinical outcomes of patients per EBMT Criteria* Allocation Number Age Baseline Myeloma Stage Prior Systemic Therapies Prior Bone Marrow Transplant Baseline β2-microglobulin On-study Duration (days) Best Response EBMT = European Group for Blood and Marrow Transplantation; MR = Minimal Response; ND = Not Determined; NE = Not Evaluable; SD = Stable Disease. *Cohorts 3, 5, and 6 were not initiated. Cohort 1 (200 mg twice daily x 5 days/week)     1001 55 III 12 1 ND 41 NE     1002 47 II 3 1 2.0 254 SD     1003 64 III 4 0 2.6 62 SD Cohort 2 (250 mg twice daily x 5 days/week)     1004 38 I 5 0 1.7 55 SD     1005 74 III 7 1 6.7 240 MR     1006 65 ND 7 2 3.3 74 NE     1007 67 ND 1 0 10.1 118 SD     1008 42 III 5 0 4.7 109 SD     1009 50 III 5 0 1.4 123 SD Cohort 4 (200 mg twice daily x 14 days/3 weeks)     861 69 IIIa 16 1 4.6 56 SD     862 63 IIIa 20 1 3.1 25 NE     863 61 IIIa 10 1 2.7 62 SD     864 71 IIIa 16 1 11.0 155 SD

Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 8132-8132 ◽  
Author(s):  
J. J. Shah ◽  
A. D. Cohen ◽  
J. A. Zonder ◽  
J. L. Kaufman ◽  
S. M. Burt ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Trial ◽  
Refractory Multiple Myeloma

A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8532-8532 ◽  
Author(s):  
Thomas G. Martin ◽  
Karl Hsu ◽  
Stephen Anthony Strickland ◽  
Martha Jane Glenn ◽  
Joseph Mikhael ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Phase I ◽  
Phase I Trial ◽  
Refractory Multiple Myeloma

A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

2009 ◽  
Vol 9 ◽  
pp. S86 ◽  
Author(s):  
AM Roccaro ◽  
R Leduc ◽  
M Nelson ◽  
A Sam ◽  
S Chuma ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Trial ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document